Plasma Cell Leukemia
42
19
21
12
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
2.4%
1 terminated out of 42 trials
92.3%
+5.8% vs benchmark
0%
0 trials in Phase 3/4
67%
8 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (42)
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia
Expanded Access to Venetoclax
Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
European Myeloma Network (EMN) Sample Project
Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma
Registry for Adults With Plasma Cell Disorders (PCD's)
Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma
High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia
A Study of CT0596 in Plasma Cell Leukemia
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Allo HSCT Using RIC and PTCy for Hematological Diseases
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia